geneType

Business Update

February 1, 2024

Authorised by the Board of Directors of Genetic Technologies Limited

ASX: GTG
NASDAQ: GENE

Genetic Technologies

Notice: Forward looking statements

The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited (the Company) ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by the Company and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company's filings to the ASX and SEC for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by the Company. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Key Messages

- Executing our Vision and Strategy to be leader in personalized predictive genomics
- Our journey from R&D → Commercialization and the pathway to profitability
- Milestones include:
  - Precision Medicine launch with Major Private Hospital
  - GeneType Multi-test with 3 NEW tests – Approved in Australia
  - Ambassador to promote Melanoma this Summer
  - Industry Partner in Multi Cancer Risk trial
  - Major breakthrough - geneType Predicting Risk of Pancreatic Cancer
- A global operation, a comprehensive human and animal health portfolio
  - New Market opportunities in S.E.A and UK
- Engaged with leading global collaborations
- Continuing our journey with a strong commitment to ESG principals
- Have a well-defined strategic plan to execute on a multi brand strategy in key regions

World leader in personalized predictive genomics. Empowering individuals to take control of their health.

UNIQUE VALUE PROPOSITION

Turning cutting-edge science into personalized, predictive tests driven by AI & machine learning techniques.

Backed by over 20 years of experience, our scientific and clinical teams are translating genetics and clinical information into absolute risk tests that predict risk of chronic diseases before onset.

Empowering physicians to improve health outcomes for people around the world enabling a new era of personalised medicine.

World leading portfolio

Most comprehensive guideline driven portfolio for human and animal health.

- Patented GeneType Multi Risk Test
- Non-Invasive Prenatal Testing (NIPT)
- Carrier screen testing
- Pharmacogenomics
- Oncogenetic & Monogenic diseases
- Pet care

Revenues anchored by our 3 brands to seize a multi Billion-dollar opportunity.

geneType EasyDNA AffinityDNA

Global Overview

60
Employees (FTE) globally

40
Countries

25
Patents Granted*
(9 Pending Worldwide*)

14
Test Categories

51
Tests

12
Partner Laboratories

* Patents granted are specific to the GeneType portfolio of products

Highlights – Half 1 FY24 ending December



CASH RECEIPTS**
H1 A$3.9m

CASH BALANCE
A$3.7m*

GROSS MARGIN
A$2.1m

GROSS MARGIN
51% (+4ppt)

- Cash Receipts totalling A$3.6m for the Quarter ending December 2023
  - Receipts from customers A$1.85m
  - R&D Tax Incentive of A$1.75 million received.
- Appointment of 2 experienced commercial advisors to accelerate our Direct to Consumer ('DTC') plans for GeneType in the U.S.
- Record number of geneType tests processed, with six times more commercial samples received compared to the prior period.
- Launched Hereditary Breast & Ovarian Cancer Risk Assessment Test (HBOC) via an exclusive Santa Monica event for a select clinicians.
- Commenced Precision Medicine Pilot with the Gold Coast Private Hospital, a member of Healthscope.
- Expanding Global Footprint South East Asia. Discussions continue with potential partners to access Indonesia's healthcare market, with the geneType Multi-Risk test
- Expanding Global Footprint UK. In April 2024 the Company's branded tests are to be offered to subscribers of the UK National Pharmacies Association (NPA).
- Commenced Activities associated with CASSOWARY Trial. MRFF Grant named GTG as sole industry partner for the $2.4 million clinical trial. Results will inform how cancer risk is assessed and has the potential to reshape care in General Practice.

* December 2023 half year $3.7million as announced on 31 January 2024
** Excludes A$1.75m R&D Tax Incentive received in December 2023

Our Pathway to Profitability

Our Journey from Extensive R&D to Revenue and Profitability

Research, Development and Innovation

2000 - 2021

Pioneers in Genomics, participating in the very 1st International Human Genome.

Investing more than 20 years in extensive R&D and Innovation

2021

Launched Patented Genetype Multi Risk Test covering 9 diseases and up to 70 annual Mortalities and Morbidities

Acquired EasyDNA Global Direct to consumer genomics

Commercialisation and Revenue Generation

2022

Acquired Affinity DNA Global Direct to consumer genomics

Developed commercial Pathways for the whole portfolio

Delivering group revenues of AUD $6.8m year ending 30 June 2022

Pathway to Profitability

2023

Developing Building the US and Australian B2B markets for GeneType

Delivering group revenues of AUD $8.7m year ending 30 June 2023

2024 - 2025

Our Pathway to profitability Executing on our 5 strategic Pillars

People and Culture
Whole of Life Portfolio
Engaging our Stakeholders
Sales and Marketing Excellence
Systems and Processes

Revenue Drivers and our Pathway to Profitability



This excludes ANY NEW Markets e.g. India, SEA or UAE
*Cash Flow positive will rely on the execution of a large payer group in the US within the next 12 months
HBOC – Hereditary Breast and Ovarian Cancer

Environmental, Social & Governance

Highlights:

- Board and Executive teams clearly defined our vision and purpose
- Introduced updated Maternity Leave Policy exceeding mandatory level, addressing Pay Equity
- Conducted Cybersecurity Training, addressing Risks and Opportunities

Focus areas for H1 FY24

- Board Composition
- Ethical Behaviour (policy review)
  - Code of conduct
  - Whistle Blower
  - Antibribery
- Diversity & Inclusion
  - Culture and Engagement Survey



Stakeholder Capitalism Metrics ESG Framework

Major Milestones

Precision Medicine Launch with Major Private Hospital

Pioneering Precision Medicine - Prestigious initiative for the hospital

Commenced our Pilot study:

- Patented geneType Multi-risk test Combining Clinical and Genetic risk
- 9 Diseases - Oncology, Cardiovascular, and Metabolic risk assessment
- Combined with; Pharmacogenomics (PGx) tests,

Providing a comprehensive risk and wellness profile for Gold Coast Private Hospital

Major Milestones
Expanded geneType Multi-test Approved

Announced that the expanded geneType Multi-Risk Test is now available to order in Australia. GTG announced the launch of the expanded test in the U.S., to include three new diseases, in March 2023.

The three new diseases
- Pancreatic Cancer
- Melanoma
- Atrial Fibrillation

Approved for sale in Australia by the National Association of Testing Authority (NATA).

Major Milestones

Sole Industry Partner in $2.4m Multi Cancer Risk Clinical trial

Medical Research Future Fund (MRFF) Genomics Health Futures Mission Grant has been awarded.

The grant will provide funding for a randomized controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice.

GENE is the sole industry partner for trial which is to be led by Professor Jon Emery.

Successful outcomes from the trial could lead to the implementation of geneType into routine use in General Practice in Australia.

Major Milestones

Publication GeneType Predicting Risk of Pancreatic Cancer

GeneType's Pancreatic Cancer risk assessment showed nearly 50% improvement in identifying patients at high risk.

The study evaluated close to 380,000 adults aged 40 to 69 years from the UK Biobank, identifying 851 incident cases of pancreatic cancer, providing a very powerful validation.

The paper entitled "Predicting 10-year risk of pancreatic cancer using a combined genetic and clinical model" was published in the journal Gastro Hep Advances.[1]

GeneType's Pancreatic Cancer risk assessment will help doctors diagnose pancreatic cancer earlier, intervene earlier and help reduce this cancer's appalling mortality.

[1] https://go.redchip.com/e/136741/0s1KElQmh-iigJ5Z3fCSFBqV02qDsr/6hj73k/690066934/h/FHRNJq9iJwj_Wr0LaXviC7tKUd_jdGtOaXMiUrRI-9s

Ambassador - GeneType for Melanoma

Campaign to promoted the Early Detection of Melanoma

Driving awareness of Melanoma in the Summer of 2023 focusing on TV, Radio and Print media

Deborah revealed that the two cancers on her face were undetectable to the naked eye.

Deborah's shares a graphic shot is a poignant reminder to all Australians to have their skin checked, even if nothing is evident on the surface.

As for post-surgery scarring, Deborah revealed: “My skin will heal and in the coming months you’ll hardly see the scar.

Exploring NEW markets – Southeast Asia

Exclusive networking event in Jakarta, Indonesia - Uniting innovation

- The keynote address was by Budi Sadikin, Minister of Health, Ministry of Health of the Republic of Indonesia
- Southeast Asian healthcare market projected to reach USD 270 Billion by 2027

Partnering to construct an MoU

- Licence agreement for Indonesian Healthcare System
- Longevity Bio Bank

Exploring NEW markets - UK Pharmacy Expansion

EasyDNA / Affinity DNA and Genetype

- Across 10,000 geared at helping patients increase their general health and wellbeing.
- The focus areas being disseminated through the NPA's 10,000+ pharmacies is Home Testing, where geneType / EasyDNA / Affinity DNA will feature prominently
- These brands will be featured as the thought leader, giving us a way to speak directly to the public:
- Launch dates:
- April 2024 (digital guides), with a guaranteed minimum of 3 million* distribution for 12 months.
- April 2024 (hard copies), with a minimum of 400,000* hard copies for 12 months.

Pathways to Market

Executing a multi-brand strategy

Medical & Payer Business to Business (B2B)

geneType

Oncology – GTG
Cardiovascular
Prenatal NIPT
Carrier testing
Clinical & Molecular
Metabolic

Consumer initiated testing (CIT)

with medical supervision

geneType

Expanded Carrier testing & NIPT
Oncology – Multi-test
Cardiovascular – Multi-test
Metabolic – Multi-test
Pharmacogenomics

Direct to Consumer Testing (DTC)

with no medical supervision

EasyDNA

Ancestry
Paternity
Health & Wellbeing
Pharmacogenetics

AffinityDNA

Animal
Drug testing
Relationship
DNA Storage

B2B - US Enterprise model; market segmentation critical

Driving our Revenue Pipeline

HCP Clinics Patient Pay (3-6 months)	1. Current geneType CRM Contacts (~1,000) 2. Functional Medicine 3. Concierge Medicine 4. Longevity Clinics 5. Anti-Aging Clinics
HCP-Centric (KOL/Influencer) (6-12 months)	6. Academic Precision Medicine Programs 7. Academic medical center based high risk Women's Health Centers; 8. Imaging Centers (National, regional and health system based) 9. Nutraceutical / Supplement Industry 10. Health Systems
Employer Ecosystem (6-24 months)	11. Self-Insured Employers 12. Worksite Health Centers(WHC) 13. Employer Healthcare Coalitions 14. Employee Wellbeing/ Wellness Vendors 15. EBC/Broker

Our Innovation – Multi-Risk Test

GeneType can identify patients 'at risk' before onset and aid in the early detection and treatment.

GeneType Risk assessment test for breast cancer has demonstrated improved early-stage detection by 18% and saving approx. US$1.4B per annum[4] for the US payer

Diseases Areas

Oncology

Breast Cancer
Colorectal Cancer
Prostate Cancer
Melanoma
Pancreatic Cancer
Ovarian Cancer

Cardiovascular

Atrial Fibrillation
Coronary Artery Disease

Metabolic

Type 2 Diabetes

Phase 1 Launch [2]

Phase 2 Launch [3]

GeneType Multi-test covers >70% of mortality & morbidity

Guideline driven, Actionable results

1. TGA, FDA and EU regulatory approval granted to the sponsor, DNA Genotek
2. Commercial availability
3. Commercial availability in the US and Australia
4. Budget Impact Model

NEW Comprehensive Breast and Ovarian Cancer test

Evaluates a woman's risk of developing Breast and/or Ovarian Cancer in women 30 years+

5% - Hereditary Cancer with known pathogenic variant BRCA1/2

10% - Familial cancer with no known pathogenic variant

85% - geneType Patented integrated Breast and Ovarian Risk test

- The test evaluates a women's risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mutation or from the far more common familial or sporadic cancer.
- GTG's unique approach "appends" the detection of the 13 major "actionable" Breast and Ovarian cancer susceptibility genes to the GeneType test platform.
- Advances the goal of providing population-based genetic screening where up to 85% of cancers diagnosed do not have hereditary or family history

[1] https://www.breastcancer.org/facts-statistics
Announcement - Globe Newswire

DTC - Growth strategy for EasyDNA

PHASE 1
Brand Re-Ignition

Brand Refresh

Multi-brand Portfolio

EasyDNA Brand Refresh

Test Rationalization

Website Refresh

Website Development

First-party Data Collection

Targeted Messaging

Improve User Experience & Engagement

PHASE 2
Revenue and Growth Focus

Improved Lead Gen

Google Ads
Facebook Ads

Content & Email Marketing

Influencer Marketing & Testimonials

New Sales Channels

Amazon Store Front

Target B2B Customer Segments

New Markets

Collaborations

Professor Bernard Rosner

Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA – Principal Investigator of the Nurses' Health Study (International expert in Biostatistics and breast cancer epidemiology).

Collaborating on a project to improve the GeneType Breast Cancer Test and to Cross-validate the Ovarian cancer test in the Nurses Health Study

Professor Graham Colditz

Deputy Director, Institute for Public Health. Washington University School of Medicine, St. Louis, Missouri (International expert in Biostatistics and breast cancer epidemiology).

Collaborating on a project to validate the GeneType for Breast Cancer Test in African American patients

Professor John Hopper

Professorial Fellow at the Centre for Epidemiology and Biostatistics in the School of Population Global Health, Melbourne University

Collaborating on a project to improve the Genetype for Breast Cancer Test and on a joint project with Prof Emery to develop clinical utility evidence for the GeneType tests

Professor Jon Emery

Professor of Primary Care Cancer Research at the University of Melbourne, and the Victorian Comprehensive Cancer Centre

Collaborating on a joint project with Prof Hopper to develop clinical utility evidence for the GeneType tests

Memorial Sloane Kettering Cancer

Collaborating on a project to investigate modification of risk in BRCA-positive patients by polygenic risk scores

Ohio State University

Collaborating on a project to investigate modification of risk in BRCA-positive patients by polygenic risk scores

Snapshot and Achievements last 12 months

GeneType & Commercialization

- ✓ FY23 Group Receipts A$8.8 million, up 29%
- ✓ GeneType risk test: +250% in commercial samples received in June quarter
- ✓ 9 geneType Multi-Risk tests NOW commercially available in the US and Australian Markets
- ✓ >100 medical practices on-boarded launching the foundation of geneType Hubs
- ✓ Launched U.S TV campaign

EasyDNA & Affinity DNA

- ✓ Integrated 2 Acquisitions
- ✓ NEW EasyDNA Website
- ✓ NEW eCommerce Platform
- ✓ Launch Carrier Testing and Non-Invasive Prenatal Tests (NIPT) into Europe
- ✓ Launch DNA storage solution in GTG NATA approved facility

Reimbursement activation

- ✓ Independently developed Budget Impact Model (BIM) identifies US$1.4 billion dollars in annual savings in the treatment of breast cancer
- ✓ Active payer and distribution conversations
- ✓ Progress on US Payer meetings to enable coverage across millions of lives

Partnerships and Conferences

- ✓ Partnerships with Australian Breast Care Centre and Dr Nicole Yap
- ✓ Screening for breast cancer risk with Prof Bruce Mann at Royal Women's Hospital in Melbourne
- ✓ The American Society of Clinic Oncologists (ASCO) in Chicago
- ✓ Biotechnology Innovation Organisation (BIO) conference in Boston
- ✓ International Congress of Genomics (ICG)

Clinical Validity and IP Strategy

- ✓ 9 Peer reviewed publication in 12 months
- ✓ Submitted geneType risk test to NCCN Guidelines
- ✓ Publications:
  - ✓ PLOS ONE
  - ✓ Journal or Precision Medicine
  - ✓ European Journal of Cancer prevention
  - ✓ Journal Breast Cancer Research and Treatment
- ✓ 25 Patents granted or pending

Laboratory Capability

- ✓ Gained NATA and CMS-CLIA accreditation and certification for 6 polygenic risk score tests
- ✓ Successful ARTG notification to TGA for company IVDs for all tests on the multi-risk test

Summary

- Developed a clear Vision and Strategy to be leader in personalized predictive genomics
- Identified the Drivers of Revenue and pathway to profitability by the middle of FY25
- Strong momentum in commercial operations with +29% growth in customer receipts
- We have a global operation, a comprehensive human and animal health portfolio
- Engaged with leading global collaborations
- Begun a journey with a strong commitment to ESG principals
- Have a well-defined strategic plan to execute on a multi brand strategy in key regions

Thank you & Questions

Investor Relations
Adrian Mulcahy
Market Eye – Automic Group
M: +61 438 630 422
E: adrian.mulcahy@automicgroup.com.au

www.linkedin.com/company/genetype-limited

www.genetype.com

Appendices

Board and Management:
Sales and Scientific expertise leading GTG

Mr. Peter Rubinstein
BEc, LLB
Chairman
Non – Executive Director

Dr. Lindsay Wakefield
MBBS
Non – Executive Director

Mr Nick Burrows
B.Comm, FAICD, FCA, FGIA, FTIA, F Fin
Non – Executive Director

Simon Morriss
GAICD
Chief Executive Officer

Dr. Jerzy "George" Muchnicki
MBBS
Non-Executive Director



Erika Spaeth
PhD
Director of Clinical & Scientific Affairs

Richard Allman
BSc, PhD
Scientific Advisor

Tony Di Pietro
B. Comm, CA, AGIA, MAICD
CFO & Company Secretary

Carl Stubbings
Chief Commercial Officer

Strong Scientific Leadership: Advisory Board

Professor Jon Emery

MBBCh MA DPhil FRACGP MRCGP
Research & Education Lead, Primary Care Integration, Victorian Comprehensive Cancer Centre Herman Chair of Primary Care Cancer Research, University of Melbourne

Professor Finlay Macrae AO

MBBS, MD, FRACP, FRCP, AGAF MWGO is Principal Fellow and Professor, Department of Medicine, University of Melbourne, and Head of Colorectal Medicine and Genetics, The Royal Melbourne Hospital

Ora K. Gordon, M.D.

MD, MS, FACMG
Regional Medical Director, Center for Clinical Genetics & Genomics. Clinical Director, PSJH Population Health Genomics Program. Chair, Integrated Network Cancer Program, Professor of Genetics, St John Cancer Institute



A.Prof Ron Dick

MBBS, FRACP, FCSANZ, Chairman of Cardiovascular Institute at Epworth Healthcare, an Honorary Cardiologist at the Alfred Hospital and Bendigo Healthcare Group.

Completed his MBBS in 1979 and became a Fellow of the Australian College of Physicians in 1986. His interventional cardiology fellowship was from the University of Michigan Medical Centre USA.

Financial Overview

- Net cash outflow of A$4.1 million for the 6 months to 31 December 2023. Receipts from customers relate to EasyDNA and Affinity DNA branded sales. We continue to develop and commercialize our geneType tests.

- Cash reserves will be directed:
  - to support the commercialization of the GeneType Multi Risk test through the B2B channels with payers, insurers and employers in the United States and expand into Europe;
  - to accelerate our Direct to Consumer ('DTC') plans for Genetype in the U.S., capitalising on the burgeoning consumer personalised health and wellness sector;
  - for funding product research and development;
  - to increase our sales and marketing presences and drive of its tests via the consumer-initiated testing platforms;
  - to execute the go to market, sales and marketing to launch the Comprehensive Hereditary Breast and Ovarian Cancer Risk Test as part of our germline genetic testing division; and
  - for other working capital and general corporate purposes.

A$'000	31-December-23	31-December-22	Change
Net operating cashflow[1]	(4,071)	(6,220)	35%
Receipts from customers[1]	3,880	4,455	13%
Cash	3,729	5,045	26%

[1] Based on figures reported in the company's quarterly Appendix 4C

Corporate Overview



Dual Listed on the ASX and Nasdaq

Financial Information	
Share price (AUD) as at 31 January 2024	11.0c
ADR price (USD) as at 31 January 2024	$1.95
Ord Shares on Issue (M)	115
ASX 52-week trading (AUD low/high)	9.5/90c
Nasdaq 52-week trading (USD low/high)	1.81/12.00
Market Cap (AM/USM)	**12.7/8.4**
Cash at 31 December 2023	A$3.7m
Cash at 30 June 2023	A$7.9m
Debt (30 June 2022 and 30 June 2023)	nil

Note - BNY is the nominee holder for ADS Shareholders in the US

Our Intellectual Property

4 Patents granted in the US

- Patent No: US 11,257,569, Methods of assessing risk of developing a severe response to Coronavirus infection
- Patent No: US 11,072,830, Methods for breast cancer risk assessment
- Patent No: US 10,683,549, Methods for assessing risk of developing breast cancer
- Patent No: US 10,920,279, Methods for assessing risk of developing breast cancer

2 Patents granted in PRC (China & HK)

- Patent No. 201080033130.5 Methods for Breast Cancer Risk Assessment
- Patent No. 201580063966.2 Methods for assessing risk of developing breast cancer

9 Patent families pending

- Breast cancer risk assessment
- Methods for assessing risk of developing prostate cancer
- Methods for assessing risk of developing ovarian cancer
- Methods of assessing risk of developing a severe response to Coronavirus infection
- Methods of assessing risk of developing a disease
- Methods for assessing risk of developing breast cancer
- Improved methods for assessing risk of developing breast cancer
- Methods of assessing risk of developing breast cancer
- Methods for assessing risk of developing colorectal cancer

* Patents granted are specific to the GeneType portfolio of products

Defined Terms

Common Complex Diseases (CCP) – A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease.

Polygenic risk score - a number associated with one's disease risk based on the aggregated effects of individual risk variants through a multiplicative algorithm.

Variant - Single Nucleotide Polymorphism (SNP), an alteration in DNA that may be a common or rare event.

Genomic - pertaining to function of genetics from structure to relationship between genetic events.

Genetic - pertaining to a gene.

GWAS - genome-wide association studies are large population level studies which enable scientists to identify genes and genetic markers involved in human disease. This method searches the genome for SNPs that occur more frequently in people with a particular disease than in people without the disease. Each study can look at hundreds or many thousands of SNPs at the same time. Researchers use data from this type of study to pinpoint genetic variations that may contribute to a person's risk of developing a certain disease.

SNP - Single Nucleotide Polymorphisms, frequently called SNPs (pronounced "snips"), are the most common type of genetic variation among people. Each SNP represents a difference in a single DNA building block, called a nucleotide. For example, a SNP may replace the nucleotide cytosine (C) with the nucleotide thymine (T) in a certain stretch of DNA.

Serious Disease Risk (SDR) - Risk associated with acquiring COVID-19 and requiring hospitalization withs its associated morbidities and mortalities.

Germline Testing – Germline testing is done on cells that do not have cancer. It is done to see if a person has a gene mutation that is known to increase the risk of developing cancers and other health problems. This test uses cells (such as blood or skin cells) that do not have any cancer cells. Germline mutations can sometimes be passed down from parents.

Clinical Laboratory Improvement Amendments (CLIA) - Regulates laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing.

National Association of Testing Authorities (NATA) - the authority responsible for the accreditation of laboratories, inspection bodies, calibration services, producers of certified reference materials and proficiency testing scheme providers throughout Australia. It is also Australia's compliance monitoring authority for the OECD Principles of GLP. NATA provides independent assurance of technical competence through a proven network of best practice industry experts for customers who require confidence in the delivery of their products and services.

Next Generation Sequencing (NGS) – Next-generation sequencing (NGS), also known as high-throughput sequencing, is the catch-all term used to describe a number of different modern sequencing technologies. These technologies allow for sequencing of DNA and RNA much more quickly and cheaply than the previously used Sanger sequencing, and as such revolutionised the study of genomics and molecular biology.

Laboratory Developed Tests (LDT) – A type of in-vitro diagnostic test that is designed, manufactured and used within a single laboratory.

Consumer Initiated Tests (CIT) - laboratory testing that is initiated by the consumer without a physician order but reviewed and communicated back to the consumer via a physician.

Direct to Consumer (DTC) – laboratory testing that is initiated by the consumer without a physician order. The results are reported back directly to the consumer.

Health Care Professionals (HCP) – physician, GP, or specialist authorized to receive the patient results.